Eli Lilly And Stock Today

LLY Stock  USD 758.86  0.73  0.1%   


14 of 100


Odds Of Distress

Less than 3

Very Low
Eli Lilly is trading at 758.86 as of the 12th of April 2024; that is -0.1 percent decrease since the beginning of the trading day. The stock's open price was 759.59. Eli Lilly has a very small chance of experiencing financial distress in the next few years and had a good performance during the last 90 days. Equity ratings for Eli Lilly and are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 13th of March 2024 and ending today, the 12th of April 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
13th of January 1978
Health Care
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana. Eli Lilly operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. The company has 950.77 M outstanding shares of which 5.42 M shares are now shorted by investors with about 1.82 days to cover. More on Eli Lilly and

Moving together with Eli Stock

  0.8VKTX Viking Therapeutics Financial Report 24th of April 2024 PairCorr
  0.82VXRT Vaxart Inc Financial Report 2nd of May 2024 PairCorr

Moving against Eli Stock

  0.85DVAX Dynavax Technologies Financial Report 7th of May 2024 PairCorr
  0.71VRDN Viridian Therapeutics Financial Report 14th of May 2024 PairCorr
  0.68EVO Evotec SE ADRPairCorr
  0.63VRAX Virax Biolabs Group Fiscal Year End 12th of June 2024 PairCorr
  0.59VIRI Virios Therapeutics Llc Financial Report 9th of May 2024 PairCorr
  0.43JNJ Johnson Johnson Earnings Call This WeekPairCorr

Eli Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Eli Lilly's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Eli Lilly or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary, Eli Lilly's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Eli Lilly's managers, analysts, and investors.
Environment Score
Governance Score
Social Score
CEOJacob Naarden
Thematic Ideas
(View all Themes)
Old Names[Eli Lilly and Company, Eli Lilly and Company]
Business ConcentrationPharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, SP 500 Index, SP 100 Index, SP 100, ARCA Pharmaceutical, NYSE 100 Index, Compulsion, Healthcare, ESG Investing, Health Care, Pharmaceuticals, Drug Manufacturers—General, Healthcare (View all Sectors)
Excise Tax ActivitiesAnimal Testing
Average Analyst Recommendation
Analysts covering Eli Lilly report their recommendations after researching Eli Lilly's financial statements, talking to executives and customers, or listening in on Eli Lilly's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Eli Lilly. The Eli consensus assessment is calculated by taking the average forecast from all of the analysts covering Eli Lilly.
Financial Strength
Based on the key measurements obtained from Eli Lilly's financial statements, Eli Lilly and is doing better financially then in previous quarter. It has a moderate probability of reporting better financial numbers in May. Financial strength of Eli Lilly is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.70.5331
Significantly Up
Slightly volatile
Gross Profit Margin0.620.8073
Way Down
Pretty Stable
Total Current Liabilities28.7 B27.3 B
Sufficiently Up
Slightly volatile
Non Current Liabilities Total27.1 B25.8 B
Sufficiently Up
Slightly volatile
Total Assets67.2 B64 B
Sufficiently Up
Slightly volatile
Total Current Assets27 B25.7 B
Sufficiently Up
Slightly volatile
Total Cash From Operating Activities4.3 B4.2 B
Fairly Up
Slightly volatile
Eli Lilly's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Eli Lilly's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Eli Lilly's bond ratings measure its overall creditworthiness, which in many ways corresponds to the cost of borrowing for an issuer. These ratings assign a letter grade to all of Eli Lilly's outstanding corporate bonds that indicate their credit quality. We use reports published by private self-sufficient rating services such as Standard & Poor's or Fitch Ratings Inc. to evaluate a bond issuer's financial strength or its ability to pay a bond's principal and interest.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Eli Lilly's financial leverage. It provides some insight into what part of Eli Lilly's total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on Eli Lilly's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Eli Lilly deploys its capital and how much of that capital is borrowed.
Eli Lilly cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company has 25.23 B in debt with debt to equity (D/E) ratio of 1.58, which is OK given its current industry classification. Eli Lilly has a current ratio of 1.11, demonstrating that it may not be capable to disburse its financial commitments when the payables are due. Debt can assist Eli Lilly until it has trouble settling it off, either with new capital or with free cash flow. So, Eli Lilly's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Eli Lilly sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Eli to invest in growth at high rates of return. When we think about Eli Lilly's use of debt, we should always consider it together with cash and equity.

Capital Expenditures

7.76 Billion
Eli Lilly and (LLY) is traded on New York Stock Exchange in USA. It is located in Lilly Corporate Center, Indianapolis, IN, United States, 46285 and employs 43,000 people. Eli Lilly is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with a total capitalization of 722.19 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Eli Lilly's market, we take the total number of its shares issued and multiply it by Eli Lilly's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Eli Lilly runs under Pharmaceuticals sector within Health Care industry. The entity has 950.77 M outstanding shares of which 5.42 M shares are now shorted by investors with about 1.82 days to cover. Eli Lilly and has about 2.07 B in cash with 4.24 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.97.
Check Eli Lilly Probability Of Bankruptcy
Ownership Allocation
Eli Lilly retains a total of 950.77 Million outstanding shares. The majority of Eli Lilly and outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Eli Lilly to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Eli Lilly. Please pay attention to any change in the institutional holdings of Eli Lilly and as this could imply that something significant has changed or is about to change at the company. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.
Check Eli Ownership Details

Eli Stock Price Odds Analysis

Based on a normal probability distribution, the odds of Eli Lilly jumping above the current price in 90 days from now is about 28.5%. The Eli Lilly and probability density function shows the probability of Eli Lilly stock to fall within a particular range of prices over 90 days. Considering the 90-day investment horizon Eli Lilly has a beta of 0.7212. This indicates as returns on the market go up, Eli Lilly average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Eli Lilly and will be expected to be much smaller as well. Additionally, eli Lilly and has an alpha of 0.24, implying that it can generate a 0.24 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
  Odds Below 758.86HorizonTargetOdds Above 758.86
71.35%90 days
Based on a normal probability distribution, the odds of Eli Lilly to move above the current price in 90 days from now is about 28.5 (This Eli Lilly and probability density function shows the probability of Eli Stock to fall within a particular range of prices over 90 days) .

Eli Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Eli Lilly that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Eli Lilly's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Eli Lilly's value.
InstituionRecorded OnShares
Geode Capital Management, Llc2023-12-31
16 M
Morgan Stanley - Brokerage Accounts2023-12-31
12.7 M
Wellington Management Company Llp2023-12-31
11.8 M
Norges Bank2023-12-31
10.3 M
Bank Of America Corp2023-12-31
9.9 M
Goldman Sachs Group Inc2023-12-31
9.4 M
Northern Trust Corp2023-12-31
9.1 M
Jennison Associates Llc2023-12-31
7.6 M
Capital Research Global Investors2023-12-31
7.6 M
Lilly Endowment Inc2023-12-31
99.8 M
Vanguard Group Inc2023-12-31
71.6 M
View Eli Lilly Diagnostics

Eli Lilly Historical Income Statement

Eli Lilly and Income Statement is one of the three primary financial statements used for reporting Eli's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Eli Lilly revenue and expense. Eli Lilly Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Eli Lilly's Discontinued Operations is fairly stable compared to the past year. Reconciled Depreciation is likely to rise to about 1.6 B in 2024, whereas Depreciation And Amortization is likely to drop slightly above 994.5 M in 2024. View More Fundamentals

Eli Stock Against Markets

Picking the right benchmark for Eli Lilly stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Eli Lilly stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Eli Lilly is critical whether you are bullish or bearish towards Eli Lilly and at a given time. Please also check how Eli Lilly's historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Eli Lilly without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Volatility Analysis Now


Volatility Analysis

Get historical volatility and risk analysis based on latest market data
All  Next Launch Module

Eli Lilly Corporate Directors

Eli Lilly corporate directors refer to members of an Eli Lilly board of directors. The board of directors generally takes responsibility for the Eli Lilly's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Eli Lilly's board members must vote for the resolution. The Eli Lilly board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Ralph AlvarezIndependent DirectorProfile
Jamere JacksonIndependent DirectorProfile
Juan LucianoLead Independent DirectorProfile
Karen WalkerIndependent DirectorProfile

How to buy Eli Stock?

Before investing in Eli Lilly, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Eli Lilly. To buy Eli Lilly stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Eli Lilly. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Eli Lilly stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Eli Lilly and stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Eli Lilly and stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Eli Lilly and, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Eli Stock please use our How to Invest in Eli Lilly guide.

Already Invested in Eli Lilly and?

The danger of trading Eli Lilly and is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Eli Lilly is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Eli Lilly. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Eli Lilly is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Eli Lilly offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eli Lilly's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eli Lilly And Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eli Lilly And Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly and. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

Complementary Tools for Eli Stock analysis

When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
CEOs Directory
Screen CEOs from public companies around the world
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Is Eli Lilly's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eli Lilly. If investors know Eli will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eli Lilly listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
Dividend Share
Earnings Share
Revenue Per Share
Quarterly Revenue Growth
The market value of Eli Lilly is measured differently than its book value, which is the value of Eli that is recorded on the company's balance sheet. Investors also form their own opinion of Eli Lilly's value that differs from its market value or its book value, called intrinsic value, which is Eli Lilly's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eli Lilly's market value can be influenced by many factors that don't directly affect Eli Lilly's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eli Lilly's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eli Lilly is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eli Lilly's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.